Abstract 2691: A randomized Phase III study comparing the efficacy of Bacillus Calmette Guérin strain Tice versus Connaught for immunotherapy of non-muscle invasive bladder cancer

Phase Iii Study ◽

795TiP Phase III study of the programmed cell death protein 1 inhibitor PF-06801591 plus bacillus Calmette-Guérin for non-muscle invasive bladder cancer

Annals of Oncology ◽

10.1016/j.annonc.2020.08.867 ◽

2020 ◽

Vol 31 ◽

pp. S604

Author(s):

G.D. Steinberg ◽

D. Saltstein ◽

N. Shore ◽

R. Cesari ◽

J. Vermette ◽

...

Keyword(s):

Bladder Cancer ◽

Cell Death ◽

Programmed Cell Death ◽

Phase Iii ◽

Invasive Bladder Cancer ◽

Phase Iii Study ◽

Muscle Invasive ◽

Cell Death Protein

KEYNOTE-905: A phase III study of cystectomy plus perioperative pembrolizumab versus cystectomy alone in cisplatin (cis)-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC)

Annals of Oncology ◽

10.1093/annonc/mdz249.085 ◽

2019 ◽

Vol 30 ◽

pp. v401

Author(s):

M. Galsky ◽

A. Necchi ◽

N.D. Shore ◽

F. Witjes ◽

K. Nam ◽

...

Keyword(s):

Bladder Cancer ◽

Phase Iii ◽

Invasive Bladder Cancer ◽

Phase Iii Study ◽

Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A multicenter phase III study

International Journal of Urology ◽

10.1111/iju.13718 ◽

2018 ◽

Vol 25 (8) ◽

pp. 723-729 ◽

Cited By ~ 17

Author(s):

Yasushi Nakai ◽

Keiji Inoue ◽

Toyonori Tsuzuki ◽

Tsutomu Shimamoto ◽

Taro Shuin ◽

...

Keyword(s):

Bladder Cancer ◽

Aminolevulinic Acid ◽

Phase Iii ◽

Invasive Bladder Cancer ◽

Photodynamic Diagnosis ◽

Fluorescence Cystoscopy ◽

Multicenter Phase ◽

Phase Iii Study ◽

PD12-07 A PHASE III STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC FOR PATIENTS WITH HIGH-GRADE, BCG UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER

The Journal of Urology ◽

10.1097/ju.0000000000000846.07 ◽

2020 ◽

Vol 203 ◽

pp. e261-e262 ◽

Cited By ~ 1

Author(s):

Stephen Boorjian* ◽

Colin Dinney

Keyword(s):

Bladder Cancer ◽

Phase Iii ◽

Invasive Bladder Cancer ◽

High Grade ◽

Safety And Efficacy ◽

Phase Iii Study ◽

716TiP IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti–PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA+ post cystectomy

Annals of Oncology ◽

10.1016/j.annonc.2021.08.112 ◽

2021 ◽

Vol 32 ◽

pp. S721

Author(s):

T.B. Powles ◽

J.E. Gschwend ◽

S. Bracarda ◽

D. Castellano ◽

M. Gross-Goupil ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Adjuvant Therapy ◽

Phase Iii ◽

Invasive Bladder Cancer ◽

Double Blind ◽

Phase Iii Study ◽

Muscle Invasive ◽

Ct Dna

KEYNOTE-866: Phase III study of perioperative pembrolizumab (pembro) or placebo (pbo) in combination with neoadjuvant chemotherapy in cisplatin (cis)-eligible patients (pts) with muscle-invasive bladder cancer (MIBC)

Annals of Oncology ◽

10.1093/annonc/mdz249.084 ◽

2019 ◽

Vol 30 ◽

pp. v401

Author(s):

A.O. Siefker-Radtke ◽

G. Steinberg ◽

J. Bedke ◽

H. Nishiyama ◽

J. Martin ◽

...

Keyword(s):

Bladder Cancer ◽

Neoadjuvant Chemotherapy ◽

Phase Iii ◽

Invasive Bladder Cancer ◽

Phase Iii Study ◽

Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial

European Urology ◽

10.1016/j.eururo.2018.09.005 ◽

2019 ◽

Vol 75 (1) ◽

pp. 63-71 ◽

Cited By ~ 28

Author(s):

Wei Shen Tan ◽

Anesh Panchal ◽

Laura Buckley ◽

Adam J. Devall ◽

Laurence S. Loubière ◽

...

Keyword(s):

Bladder Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Phase Iii ◽

Invasive Bladder Cancer ◽

Open Label ◽

Muscle Invasive ◽

Randomised Controlled

Re: Radiofrequency-Induced Thermo-Chemotherapy Effect versus a Second Course of bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-Muscle-Invasive Bladder Cancer following Induction or Maintenance bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-Label, Randomised Controlled Trial

The Journal of Urology ◽

10.1097/ju.0000000000000676 ◽

2020 ◽

Vol 203 (3) ◽

pp. 461-462

Author(s):

Sam S. Chang

Keyword(s):

Bladder Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Phase Iii ◽

Invasive Bladder Cancer ◽

Open Label ◽

Muscle Invasive ◽

Randomised Controlled

2x2 Factorial randomised phase III study comparing standard versus whole bladder volume radiotherapy with and without synchronous chemotherapy in muscle invasive bladder cancer

http://isrctn.org/> ◽

10.1186/isrctn68324339 ◽

2012 ◽

Author(s):

Rebecca Lewis

Keyword(s):

Bladder Cancer ◽

Phase Iii ◽

Bladder Volume ◽

Invasive Bladder Cancer ◽

Phase Iii Study ◽

Re: Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial

European Urology ◽

10.1016/j.eururo.2019.01.030 ◽

2019 ◽

Vol 75 (5) ◽

pp. 879-880

Author(s):

Piotr Radziszewski ◽

Sławomir Poletajew

Keyword(s):

Bladder Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Phase Iii ◽

Invasive Bladder Cancer ◽

Open Label ◽

Muscle Invasive ◽

Randomised Controlled